Exploring the Genetics of Schizophrenia in Manitoba
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Manitoba
About this trial
Schizophrenia is a serious mental illness that affects about 1 in 100 Canadians, shortens life expectancy, and places a large burden on individuals, families, and the healthcare system. Genetics are known to play a major role, but current research explains only part of the inherited risk because most studies have looked at only a small portion of the genome and have mainly focused on people outside Canada. This project will create the first large-scale Manitoba-based schizophrenia whole-genome sequencing database by studying 1,500 Manitobans with and without schizophrenia using both short-read and advanced long-read genome sequencing technologies. Researchers will combine genetic data with lifelong provincial health records to better understand rare genetic variants linked to schizophrenia and how genetic differences influence medication response, side effects, hospitalizations, and treatment outcomes. The study aims to fill important gaps in schizophrenia research in Canada, improve understanding of the disorder's biology, and support the development of more personalized and effective treatments for people living with schizophrenia.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Individuals aged 18 years and older,
Reside in Manitoba,
Involved in the EPPIS, STEP, PACT, ACT/FACTT clinics,
Clinical diagnosis of schizophrenia using standard DSM-5 criteria,
Disqualifiers
There are no specific exclusion criteria beyond meeting the inclusion criteria or not providing informed consent.
Trial population
The schizophrenia study population will consist of Manitoba residents aged 18 years and older with a clinical diagnosis of schizophrenia according to DSM-5 criteria. Participants will be recruited from the MPR, including individuals receiving care through the Early Psychosis Prevention and Intervention Service (EPPIS), Schizophrenia Treatment and Education Program (STEP), Program of Assertive Community Treatment (PACT), and Assertive Community Treatment/Flexible Assertive Community Treatment (ACT/FACT) teams. Eligible participants must be enrolled in the MPR and provide informed consent to participate in the genetic sub-study. Participants will provide saliva samples for DNA extraction and whole genome sequencing, and their genetic data will be linked with clinical, questionnaire, and provincial administrative health data to support research on the genetic basis of schizophrenia and related health outcomes.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
1,500 Participants
are grouped into 3 trial groupsGroup A: Schizophrenia (cases)
Group B: Control (screened)
Group C: Control (unscreened)
Trial outcomes
Primary outcomes
1
Genetic variation associated with schizophrenia
Identification of rare and common genetic variants through short-read and long-read whole genome sequencing. Comparison of genetic variant burden between schizophrenia cases and controls.
Time frame
through study completion, an average of 1 year2
Rare variant burden in schizophrenia
Evaluation of the frequency and distribution of rare genetic variants in individuals with schizophrenia compared with controls.
Time frame
through study completion, an average of 1 year3
Pharmacogenetic associations
Identification of genetic variants associated with antipsychotic treatment response and adverse drug reactions.
Time frame
through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Manitoba
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: